Oasmia Pharmaceutical – executive interview

Published on 27 January 2022

Oasmia Pharmaceutical is a specialty pharmaceutical company focused on developing new therapeutic options for patients suffering from hard-to-treat cancers. Oasmia has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea (paclitaxel micellar) is commercialised for ovarian cancer patients through a partnership with Elevar Therapeutics. Development programmes include Cantrixil, which is in clinical development for late-stage ovarian cancer, and Docetaxel micellar, which is in development for advanced prostate cancer.

In this interview, Oasmia’s CEO, Francois Martelet, discusses the company’s recent issue of shares with preferential rights for existing shareholders of approximately SEK151m, subject to approval at an extraordinary general meeting to be held on 21 February 2022.

Share this with friends and colleagues